Haemonetics Corporation Announces Second Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
Werte in diesem Artikel
Financial release and supplemental presentation accessible online
BOSTON, Nov. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2026, which ended September 27, 2025, are available on the Company's Investor Relations website at www.haemonetics.com.
The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on November 6, 2025.
Conference Call and Webcast Information:
- Registration: Click here to register. Upon registration, participants will receive dial-in details and a personalized PIN. While not required, joining 10 minutes prior to the event start time is recommended.
- Live webcast: Access here or through the Investor Relations section of the Haemonetics website.
A replay of the conference call and webcast will be available beginning at 11:00 a.m. ET on November 6, 2025 and will remain accessible for one year via the webcast link above.
Earnings Materials:
Haemonetics has also posted the following materials on its Investor Relations website, which will be referenced during the conference call and webcast:
- Second Quarter Fiscal 2026 Earnings Release
- Second Quarter Fiscal 2026 Supplemental Earnings Presentation
ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts: | |
Olga Guyette, Vice President-Investor Relations & Treasury | David Trenk, Manager-Investor Relations |
(781) 356-9763 | (203) 733-4987 |
Media Contact: | |
Josh Gitelson, Sr. Director-Global Communications | |
(781) 356-9776 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-corporation-announces-second-quarter-fiscal-2026-financial-results-available-on-investor-relations-website-302606803.html
SOURCE Haemonetics Corporation
Übrigens: Haemonetics und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Ausgewählte Hebelprodukte auf Haemonetics
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Haemonetics
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Nachrichten zu Haemonetics Corp.
Analysen zu Haemonetics Corp.
| Datum | Rating | Analyst | |
|---|---|---|---|
| 07.08.2019 | Haemonetics Outperform | Barrington Research | |
| 08.05.2019 | Haemonetics Outperform | Barrington Research | |
| 09.08.2018 | Haemonetics Outperform | Barrington Research | |
| 07.02.2018 | Haemonetics Outperform | Barrington Research | |
| 08.11.2017 | Haemonetics Outperform | Barrington Research |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 07.08.2019 | Haemonetics Outperform | Barrington Research | |
| 08.05.2019 | Haemonetics Outperform | Barrington Research | |
| 09.08.2018 | Haemonetics Outperform | Barrington Research | |
| 07.02.2018 | Haemonetics Outperform | Barrington Research | |
| 08.11.2017 | Haemonetics Outperform | Barrington Research |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 07.02.2017 | Haemonetics Mkt Perform | Barrington Research | |
| 07.11.2016 | Haemonetics Hold | The Benchmark Company | |
| 11.05.2016 | Haemonetics Hold | The Benchmark Company | |
| 05.11.2015 | Haemonetics Hold | The Benchmark Company | |
| 16.08.2006 | Update Haemonetics Corp.: Hold | Stanford Research |
| Datum | Rating | Analyst | |
|---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv | |||
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Haemonetics Corp. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen